Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer

NCT03167619 is registered in ClinicalTrials.gov with Duke University as lead sponsor.

NCT NCT03167619
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03167619 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer
Lead sponsor
Duke University
Phase
Phase 2
Overall status
Completed
Start date
October 4, 2018
Completion date
June 30, 2022
Enrollment
45 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer